| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Submission example | IND | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
IND Submission example | IND | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
IND Submission example | IND | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology |
Recent Updates
Recently added Catalysts
Immunome, Inc.$23.35
-0.91 (-3.76%)
C 50Pipeline Score Overvalued Biotech · Clinical
Market Cap
2.45 B
EPS
-2.38
P/E Ratio
-
Value Trade
24.31 M
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
46.38 M
Operating CF
-58.64 M
Total Assets
619.79 M
Total Liabilities
31.11 M
Equity
588.69 M
D/E Ratio
12,345
0.46 %
Week
-9.75 %
1 Month
-1.28 %
3 Month
24.05 %
6 Month
20.33 %
5 Year
38.31 %
All Time
Cash Data
Cash Position
582.69 M
Monthly Burn
19.55 M
Runway
28.1 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
1.11 M
52 Week Range
7.96 - 27.65
% held by Insiders
9.14 %
% held by Institutions
104.06 %
Enterprise Value
1.87 B
Total Shares
113.29 M
Short %
17.32 %
Float Shares
100.26 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Immunome, Inc.
160Total events
5Upcoming
41Tier-1 (high impact)
2020 – 2026Coverage
Upcoming catalysts 5
TBD
T1Full Results
Additional data from RINGSIDE to be presented at upcoming major medical conference
Event history 155
Jul 8, 2026
▲FDA Filing AcceptedvaregacestatRegulatory Filing
FDA accepted NDA for varegacestat for desmoid tumors
desmoid tumorssource ↗
Jun 11, 2026
▲First Patient Dosed-1617Trial
First patient dosed in Phase 1 trial of IM-1617
advanced solid tumorssource ↗
Jun 8, 2026
◆Oral PresentationPresentation
Presentation at Goldman Sachs 47th Annual Global Healthcare Conference
May 30, 2026
▲Oral PresentationvaregacestatPresentation
Oral presentation of detailed Phase 3 RINGSIDE data at 2026 ASCO Annual Meeting
desmoid tumorssource ↗
May 30, 2026
▲Full ResultsvaregacestatClinical Data
Detailed efficacy and safety results presented at ASCO 2026
desmoid tumorssource ↗
May 29, 2026
◆Oral PresentationvaregacestatPresentation
Oral presentation at 2026 ASCO Annual Meeting
desmoid tumorssource ↗
May 12, 2026
May 12, 2026
▲First Patient Dosed-1021Trial
Phase 1 trial of IM-1021 ongoing with objective responses observed
B-cell lymphomasource ↗
Apr 29, 2026
●NDA SubmissionvaregacestatRegulatory Filing
NDA submission to FDA for varegacestat for desmoid tumors
desmoid tumorssource ↗
Apr 29, 2026
Drug Pipeline Intelligence
C50
Pipeline Score $1.1B
Pipeline ValueOvervalued
Valuation Signal5
Drugs Scored0.5x
rNPV / MCap Top 76%
Small Cap (rank 220 of 911)
Percentile RankImmunome, Inc. carries a moderate pipeline score (50/100), with $1.8B risk-adjusted pipeline value, led by -1021 in Solid Malignancies (Phase 1), across $62B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1021 Monoclonal antibody | Solid Malignancies | Phase 1 | NCT06823167 | 13% | $948M | RECRUITING | 117 | VERY_FAST | D (27) | Feb 1, 2029 | MODERATE_RISK | LOW Jul 7, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
varegacestat | desmoid tumors | Phase 3 | 2026-04-29 | progression free survival: hazard ratio 0.16, p value <0.0001; objective response rate: varegacestat 56%, placebo 9%, p value <0.0001; median best change in tumor volume: varegacestat -83%, placebo +11%; adverse events: diarrhea 82%, fatigue 44%, rash 43%, nausea 35%, cough 34% Read More | Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors Read More | |
varegacestat | desmoid tumors | Phase 3 | 2026-04-29 | progression free survival: hazard ratio 0.16, p value <0.0001; objective response rate: varegacestat 56%, placebo 9%, p value <0.0001; median best change in tumor volume: varegacestat -83%, placebo +11%; adverse events: diarrhea 82%, fatigue 44%, rash 43%, nausea 35%, cough 34% Read More | Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors Read More | |
varegacestat | desmoid tumors | Phase 3 | 2026-04-29 | progression free survival: hazard ratio 0.16, p value <0.0001; objective response rate: varegacestat 56%, placebo 9%, p value <0.0001; median best change in tumor volume: varegacestat -83%, placebo +11%; adverse events: diarrhea 82%, fatigue 44%, rash 43%, nausea 35%, cough 34% Read More | Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IMNM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IMNM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IMNM▼ -3.8%today
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
Immunome, Inc. announced that the U.S. FDA has accepted its New Drug Application for varegacestat, a gamma secretase inhibitor aimed at treating adults with desmoid tumors. This acceptance marks a crucial step in the drug's development process. The FDA has set a target action date under the Prescription Drug User Fee Act.
Read more →IMNMImmunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
Immunome has announced the dosing of the first patient in its Phase 1 trial for IM-1617, an innovative antibody-drug conjugate targeting advanced solid tumors. This development marks a significant step in evaluating the drug's efficacy and safety profile. The trial aims to assess IM-1617's potential as a first-in-class treatment option.
Read more →IMNMImmunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
Immunome's announcement regarding the Phase 3 RINGSIDE data for Varegacestat is lacking in detail. The article does not provide any insights into the trial results or implications for adults with progressing desmoid tumors. This absence of information raises concerns about the transparency of the data presented at the ASCO Annual Meeting.
Read more →IMNMImmunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Immunome is scheduled to present at the Goldman Sachs 47th Annual Global Healthcare Conference. The event is a significant platform for companies to showcase their innovations and strategies in the healthcare sector. Further details about the presentation content or objectives were not provided.
Read more →IMNMImmunome Reports First Quarter 2026 Financial Results and Provides Business Update
Immunome has released its financial results for the first quarter of 2026, along with a business update. The report highlights the company's current financial standing and strategic direction. Further details on specific financial metrics and business initiatives were not provided in the article.
Read more →IMNMImmunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
Immunome, Inc. has submitted a New Drug Application (NDA) to the FDA for varegacestat, an oral gamma secretase inhibitor aimed at treating adults with desmoid tumors. This submission is backed by positive results from the Phase 3 RINGSIDE trial, which demonstrated significant improvements in progression-free survival and tumor response rates compared to placebo. The drug was generally well tolerated, although some adverse events were reported.
Read more →IMNMImmunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting
Immunome, Inc. announced that data from its Phase 3 RINGSIDE trial of varegacestat will be presented at the 2026 ASCO Annual Meeting. The trial focuses on treating progressing desmoid tumors and has shown positive topline results. The oral presentation is scheduled for May 30, 2026, with details on the trial's efficacy and safety to be shared.
Read more →IMNMImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome has reported inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). These grants are typically made to new employees as an incentive for joining the company. The details of the grants, including the number of shares or options, were not disclosed in the announcement.
Read more →IMNMImmunome Reports Full Year 2025 Financial Results and Provides Business Update
Immunome, Inc. reported its financial results for 2025, highlighting significant progress in its pipeline. The company announced positive Phase 3 results for varegacestat, supporting an NDA submission planned for Q2 2026. Additionally, Immunome is advancing its antibody-drug conjugate pipeline, with ongoing studies and multiple IND submissions expected in 2026.
Read more →IMNMImmunome to Present at Upcoming Investor Conferences
Immunome, Inc. announced that its management will present at two upcoming investor conferences: the TD Cowen 46th Annual Health Care Conference on March 3, 2026, and the Leerink Partners Global Healthcare Conference on March 10, 2026. Interested parties can access live webcasts of these presentations on the company's website. Immunome is dedicated to developing targeted cancer therapies.
Read more →IMNMImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 5, 2026
Immunome, Inc. has granted inducement stock options to a new employee as part of its 2024 Inducement Plan. The Compensation Committee approved these options, which total 30,000 shares at an exercise price of $26.14. The options will vest over four years, reflecting the company's commitment to attracting talent. Immunome continues to develop innovative cancer therapies.
Read more →IMNM▼ -9.1%on this newsshared move
Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Immunome, Inc. will present at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026. The company specializes in targeted cancer therapies and has a robust pipeline, including late-stage and clinical-stage therapeutics. Interested individuals can access a live audio webcast of the presentation on their website.
Read more →IMNMImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 8, 2026
Immunome, Inc. announced the grant of inducement stock options to three new employees under its 2024 Inducement Plan. A total of 93,000 shares were awarded, with an exercise price of $20.82 per share. The options will vest over four years, reflecting the company's commitment to attracting talent as it develops targeted cancer therapies.
Read more →IMNM▲ +15.7%on this news
Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors Registrational trial met primary endpoint, with varegacestat significantly improving progression-fre
Immunome has announced positive topline results from its Phase 3 RINGSIDE trial of varegacestat, highlighting its ability to significantly improve progression-free survival in patients with desmoid tumors when compared to placebo. The trial achieved an impressive objective response rate of 56% and met all key secondary endpoints. The drug displayed a manageable safety profile and was well tolerated among participants, with the most common adverse events being mild to moderate in severity. A New Drug Application is planned for submission to the U.S. FDA in Q2 2026.
Read more →IMNM▲ +15.7%on this news
Immunome Announces Proposed Public Offering of Common Stock
Immunome, a biotechnology firm specializing in targeted cancer therapies, announced plans for a $400 million underwritten public offering of common stock. The proposed offering is subject to various market conditions and includes a potential additional $60 million that underwriters may purchase. Immunome's move aims to bolster its financial position, but uncertainties regarding completion and market response remain. The company is also advancing a portfolio of promising oncology products.
Read more →IMNMImmunome Reports Third Quarter 2025 Financial Results and Provides Business Update
Immunome, Inc. (Nasdaq: IMNM) has released its financial results for Q3 2025 along with updates on its clinical pipeline. The company anticipates topline data from the RINGSIDE trial of varegacestat by year-end and has observed objective responses in ongoing trials for IM-1021. With a cash balance of $272.6 million, Immunome expects to continue operations into 2027 despite a reported net loss of $57.5 million for the quarter. Future initiatives include potential NDA submissions and the introduction of additional targeted therapies.
Read more →IMNMImmunome Reports Second Quarter 2025 Financial Results and Provides Business Update 8/6/2025 BOTHELL, Wash. – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in
Immunome, Inc. reported its financial results for the second quarter of 2025, highlighting significant progress in its clinical development programs. The company is advancing towards key milestones, including the topline data release for the RINGSIDE trial of varegacestat. This trial has received Orphan Drug Designation from both the European and U.S. regulatory bodies. With a solid cash position, Immunome plans to sustain operations through 2027 while managing a substantial net loss for the quarter.
Read more →IMNM▲ +6.4%on this news
Immunome Reports First Quarter 2025 Financial Results and Provides Business Update 5/12/2025 BOTHELL, Wash. - Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class
Immunome, Inc. has reported its financial results for the first quarter of 2025, indicating a net loss of $41.6 million amidst ongoing clinical trials. CEO Clay B. Siegall highlighted optimism for topline data from the RINGSIDE trial of varegacestat expected in the second half of 2025. The company is actively advancing its pipeline, including a recent IND clearance for IM-3050 and ongoing trials for IM-1021. With cash reserves totaling $317.3 million, Immunome expects to sustain operations through 2027.
Read more →IMNMImmunome Reports Full Year 2024 Financial Results and Provides Business Update 3/19/2025 Topline data for Phase 3 RINGSIDE study of varegacestat in progressing desmoid tumors expected in second half of 2025. First patien
Immunome, Inc. reported its financial results for the full year 2024, highlighting progress in its clinical pipeline and business strategy. The company anticipates topline data from the Phase 3 RINGSIDE study for varegacestat in the treatment of desmoid tumors in the second half of 2025. Immunome has dosed the first patient in the Phase 1 trial for its ROR1-targeted ADC, IM-1021, while other ADCs are advancing in various developmental stages. Despite a significant net loss, the company remains focused on achieving multiple clinical milestones in the upcoming year.
Read more →IMNM▼ -7.2%on this news· ran to -24% by day 3
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update 11/13/2024 BOTHELL, Wash. - Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and best-
Immunome, Inc. announced its financial results for Q3 2024, highlighting significant financial metrics and advancements in its drug pipeline. The company reported a net loss of $47.1 million while maintaining a solid cash position of $240.1 million, expected to sustain operations until 2026. Immunome expects to report topline data from its Phase 3 RINGSIDE Part B trial for AL102 in H2 2025 and is on track for IND submissions for two new candidates in early 2025. Despite notable progress, concerns regarding high operational costs and loss figures remain.
Read more →IMNMIMMUNOME, INC 2024 INDUCEMENT PLAN EFFECTIVE AS OF: OCTOBER 3, 2024 1. GENERAL. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standar
Immunome, Inc. has established a 2024 Inducement Plan effective from October 3, 2024, designed to attract new eligible employees with awards that comply with Nasdaq rules. The plan will allow for grants of various types of awards, which will require approval from Independent Directors or the Independent Compensation Committee. This strategy is aimed at securing talent while providing incentives linked to the company's stock performance.
Read more →IMNMImmunome Reports Second Quarter 2024 Financial Results and Provides Business Update 08/12/2024 BOTHELL, Wash. - Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and bes
Immunome, Inc. reported its financial results for the second quarter of 2024, highlighting the advancement of its oncology pipeline, particularly AL102. The company has successfully enrolled patients in the Phase 3 RINGSIDE Part B study for desmoid tumors, expecting topline data in the latter half of 2025. Additionally, it aims to submit IND applications for its next-generation therapies, IM-1021 and IM-3050, in early 2025. Despite these advancements, the company reported a significant net loss during the quarter, raising concerns about its financial health.
Read more →IMNM▼ -5.7%on this news
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update - Integration of AL102 and IM-1021 completed - Topline data for Phase 3 RINGSIDE trial of AL102 expected in second half of 2025 - IM-1021
Immunome, Inc. reported its financial results for Q1 2024, revealing significant advances in its cancer therapy pipeline. The integration of AL102 and IM-1021 has been successfully completed, with further developments expected for additional programs. Immunome anticipates reporting topline data for the Phase 3 RINGSIDE trial targeting desmoid tumors in the latter half of 2025. However, the company also faced a substantial net loss of $129 million during the quarter, amid ongoing investments in research and development.
Read more →IMNMfiled with Immunome's Current Report on Form 8-K with Securities and Exchange Commission ("SEC") on
Immunome, Inc. has released its full-year 2023 financial results, reporting a net loss of $106.8 million. The company is set to expect topline data for the Phase 3 RINGSIDE trial of AL102 in Q1 2025, while also planning to submit IND applications for its candidates IM-1021 and IM-3050 in the same timeframe. Immunome's cash reserves, combined with strategic acquisitions and a merger with Morphimmune, position it well for future developments in cancer therapies.
Read more →IMNM▲ +5.8%on this newsshared move
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala BOTHELL, Wash. - Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and b
Immunome, Inc. has completed the acquisition of AL102, a Phase 3 asset aimed at treating desmoid tumors, from Ayala Pharmaceuticals. The acquisition is expected to enhance Immunome's existing pipeline of targeted cancer therapies. According to the CEO, AL102 possesses the potential to establish a new standard of care and is being evaluated in the Phase 3 RINGSIDE trial. Additionally, preliminary data suggests AL102 may outperform the first FDA-approved treatment for desmoid tumors, OGSIVEO.
Read more →IMNM▲ +36.9%on this news· ran to +48% by day 1
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals - AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile - BOTHELL, WA and
Immunome has entered into a definitive agreement to acquire AL102, a Phase 3 investigational treatment for desmoid tumors, from Ayala Pharmaceuticals. The transaction involves a payment of $20 million in cash, $30 million in Immunome stock, and potential milestone payments up to $37.5 million. AL102, which is currently being evaluated in the Phase 3 RINGSIDE trial, has demonstrated promising efficacy in earlier clinical studies, showcasing high response rates. The completion of the acquisition is subject to standard conditions, including stockholder approval from Ayala.
Read more →IMNMIMMUNOME'S BUSINESS Overview We are a biopharmaceutical company focused on the development of targeted oncology therapies. We believe that the pursuit of novel or underexplored targets will be central to the next generat
Immunome is a biopharmaceutical company dedicated to developing targeted oncology therapies, including three preclinical assets. The recent acquisition of AL102, a gamma secretase inhibitor for desmoid tumors, will transition the company to clinical stage. Immunome identifies its leadership's successful track record as a valuable asset in attracting new opportunities. However, challenges remain in ensuring effective development of its candidates due to specific biological limitations.
Read more →IMNMImmunome Corporate Presentation
Immunome presented insights into its corporate strategy and pipeline during a presentation on January 11, 2024. The company aims to develop first-in-class and best-in-class oncology therapies, focusing on organic pipeline expansion coupled with strategic M&A efforts. Notably, Immunome plans to file Investigational New Drug (IND) applications for three promising programs in the first quarter of 2025. The recent acquisition of preclinical assets and positive leadership track record support their long-term goals.
Read more →IMNM▲ +7.9%on this newsshared move
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform - Exclusive worldwide license agreement for preclinical ROR1 ADC, on track to submit IND in 1Q 2025 - - Proprietary
Immunome has secured an exclusive worldwide license for Zentalis' ROR1 antibody-drug conjugate, ZPC-21, which is on track for IND submission in Q1 2025. This agreement includes an up-front payment of $35 million and potential milestone payments of up to $275 million. Dr. Clay B. Siegall highlighted the ADC's best-in-class potential while expanding Immunome's capabilities. However, the integration of ZPC-21 into Immunome's existing projects and the regulatory timeline present specific challenges.
Read more →IMNMImmunome Reports Third Quarter 2023 Financial Results - Completed merger with Morphimmune and concurrent $125 million private placement investment with leading institutional investors - - Clay B. Siegall, Ph.D., former c
Immunome, Inc. has reported its financial results for Q3 2023, highlighting a transformative merger with Morphimmune and a significant $125 million private placement investment. Dr. Clay B. Siegall, a seasoned leader in biopharma, has been appointed as Chairman and CEO, alongside other experienced executives. The merger aims to enhance Immunome's capabilities in developing targeted cancer therapies, while the company's current runway is expected to extend into Q1 2026. Despite the positive developments, the company faces challenges related to regulatory approvals and market competition.
Read more →IMNMImmunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies 10/03/2023 Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as
Immunome has successfully completed its merger with Morphimmune, marking a strategic move to enhance its oncology offerings. The merger is supported by a $125 million private investment, which involves contributions from prominent institutional investors. Dr. Clay Siegall, a veteran in the biopharma industry and former CEO of Seagen, has been appointed to lead the newly merged entity. While the merger positions Immunome for future growth in cancer therapies, various challenges remain, including regulatory hurdles and the execution of their business plan.
Read more →IMNMImmunome Reports Second Quarter 2023 Financial Results Exton, PA
Immunome, Inc. has reported its financial results for the second quarter of 2023 and shared an update on its merger with Morphimmune. The CEO expressed optimism about the merger, mentioning the potential to create innovative cancer treatments through the collaboration of their respective technologies. Immunome focuses on developing antibody therapeutics using its advanced human memory B cell platform, which is expected to improve patient outcomes in oncology. The completion of the merger is anticipated by the end of the year, positioning the combined entity for growth in the biopharmaceutical sector.
Read more →IMNM▲ +7.4%on this news
Morphimmune and Immunome Combined Corporate Presentation July 2023 MORPHIMMUNE + IMMUNOME 2 Disclaimer and Forward-Looking Statements Disclosures For the purposes of this notice, the “presentation” that fol
Morphimmune and Immunome have released a corporate presentation that highlights their combined efforts in developing a multi-faceted oncology platform. They intend to leverage a strong patent portfolio and a robust discovery engine while advancing two potential first-in-class immuno-oncology agents. The companies are well-capitalized post-PIPE, allowing them to reach critical clinical milestones in the coming years. Key opportunities for growth are expected from strategic partnerships and the expansion of their proprietary platforms.
Read more →IMNM▲ +30.3%on this newsshared move
Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies The combined company, which will operate as Immunome, will
Immunome and Morphimmune have entered into a definitive merger agreement, with a simultaneous private placement investment of $125 million aimed at enhancing their capabilities in developing targeted cancer therapies. The combined entity will continue operating under the Immunome name and will be led by Dr. Clay Siegall. This merger, expected to close by the end of Q4 2023, integrates Morphimmune’s capabilities with Immunome’s discovery platform, bolstering the company’s efforts in oncology. The additional funds will support the advancement of their combined pipeline and other operational expenses, positioning the company for future growth in drug development.
Read more →IMNMImmunome Reports First Quarter 2023 Financial Results Exton, PA
Immunome, Inc. reported its financial results for the first quarter of 2023, showing a significant increase in cash reserves and a strategic collaboration with AbbVie that strengthens its oncology research efforts. The company announced the formation of an advisory board to enhance its therapeutic target selection, showcasing a commitment to innovation. Despite a reduced net loss compared to the previous year, Immunome continues to face challenges with high operating expenses and an increasing accumulated deficit, indicating financial hurdles as it progresses in its drug development pipeline.
Read more →IMNM▲ +9.2%on this news· ran to +21% by day 1
Immunome Reports Fourth Quarter and Full Year 2022 Financial Results EXTON, Pa.
Immunome, Inc. reported its fourth quarter and full year 2022 financial results, highlighting key developments such as a partnership with AbbVie. The company anticipates an IND submission for its lead oncology program, IMM-ONC-01, which focuses on anti-IL-38 antibodies. However, it recorded substantial operating losses and increased expenses, raising concerns about its financial health as it navigates R&D challenges and market competition.
Read more →IMNMHarnessing the Power of the Human Memory B Cell JANUARY 2023 Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | immunome.com Copyright © 2023 Immunome, Inc. All rights reserved. 2 Disclaim
Immunome, Inc. is focusing on leveraging human memory B cells for novel cancer therapies, particularly targeting IL-38 for solid tumors with high unmet medical needs. Key initiatives include an IND submission planned for mid-2023 and several promising targets identified from immune responses. The management team brings extensive experience from major biopharma companies. Despite these advancements, challenges related to regulatory approvals and competition in therapeutic areas remain significant.
Read more →IMNMHarnessing the Power of the Human Memory B Cell JANUARY 2023 Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | immunome.com Copyright 2023 Immunome, Inc. All rights reserved. 2 Disclaimers and
Immunome is showcasing its research at the SITC 37th Annual Meeting, emphasizing its innovative approach to drug discovery through the Immunome Discovery Engine 2.0. The attention is on targeting ectopic proteins, particularly IL-38, which correlates with different cancer types and immune response dynamics. The platform aims to identify actionable targets for next-generation antibody-drug conjugates (ADCs) and T cell engagers (TCEs). Despite the potential, the company acknowledges various risks, including data interpretations and R&D execution challenges.
Read more →IMNMAbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets - Multi-year collaboration to identify up to 10 novel target-antibody pairs leveraging Immunome's Discovery E
AbbVie and Immunome have entered a strategic collaboration to identify up to 10 novel target-antibody pairs for oncology treatments. The partnership, enabled by Immunome's proprietary Discovery Engine, reflects AbbVie's commitment to advancing cancer therapies. As part of the agreement, Immunome will receive an upfront payment of $30 million, along with additional milestone payments based on research outcomes. This collaboration allows both companies to leverage their strengths in discovering and commercializing novel therapies for solid tumors.
Read more →IMNMHarnessing the Human Cell the Power of Memory B
Membrane Dynamics/Exosomes Elevated cell motility associated invasion and metastasis IMM20059 (anti EPN1 antibody) Metabolism High demand for materials supporting rapid tumor expansion Growth signaling 2. Immune Modulation Novel Targets 3. Discovery Engine Soluble and membrane-as
Read more →IMNMImmunome Reports Third Quarter 2022 Financial Results Exton, PA
Third Quarter 2022 Financial Results Exton, PA - November 14, 2022 - Immunome, Inc. (Nasdaq: IMNM), a clinical stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial
Read more →IMNM▲ +17.4%on this news
Immunome Reports Second Quarter 2022 Financial Results Exton, PA
Immunome Reports Second Quarter 2022 Financial Exton, PA - August 5, 2022 - Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results
Read more →IMNM▲ +12.6%on this news
Immunome's COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US, BA.4/5 and BA.2.12.1 IMM-BCP-01 neutralized BA.4/.5 and BA.2.12.1 subvariants in pseudovirus testing I
COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US, BA.4/5 and BA.2.12.1 Exton, PA - July 06, 2022 - Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and
Read more →IMNMImmunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19 First study subject has been dosed in a single dose/dose escalation study of recently diagnosed COVID-19 patients Study will eva
Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19 PA - June 09, 2022 - Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced
Read more →IMNM▲ +18%on this news
Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant 05/19/2022 - Data show that combination of two antibodie
Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant - Data show that combination of two antibodies in Immunome's cocktail successfully neutralized the Omicron varian
Read more →IMNM▲ +10.4%on this news
Immunome Reports First Quarter 2022 Financial Results Exton, PA
Reports First Quarter 2022 Financial Results Exton, PA - May 12, 2022 - Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for
Read more →IMNM▲ +23%on this news
Immunome Reports Fourth Quarter and Full Year 2021 Financial Results - Immunome Receives Safe-to-Proceed Notification from U.S. FDA for IMM-BCP-01 Investigational New Drug Application - Immunome Continues to Progress IMM
Immunome Reports Fourth Quarter and Full Year 2021 Financial Results Receives Safe-to-Proceed Notification from U.S. FDA for IMM-BCP-01 Investigational New Drug Application Continues to Progress IMM-BCP-01 Towards Phase 1b Clinical Trial - Progress on Oncology Pipeline, Includ
Read more →IMNM▼ -8%on this news
FDA Lifts Clinical Hold on Immunome's IMM-BCP-01 IND Application for the Treatment of COVID-19 Exton, PA
FDA Lifts Clinical Hold on Immunome's IMM-BCP-01 IND Application for the Treatment of COVID-19 Exton, PA - March 11, 2022 - Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibod
Read more →IMNMHarnessing the Power of The Human Memory B Cell
Immunother.(2021) 70:123 1200 1000 800 600 400 200 CD3 (/mm 2 ) LLC - vector LLC IL38 800 700 600 500 400 300 200 100 0 CD8 (/mm 2 ) LLC - vector LLC IL38 Demonstration of Anti-Tumor Activity (B16F10 Model) Induction of Anti-Tumor Memory (EMT6 Model) - Immunologically cold tumor
Read more →IMNMImmunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19 Immunome has received a clinical hold letter from the FDA requesting further information related to the prepar
Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19 PA - January 10, 2022 - Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class
Read more →IMNM▲ +12.6%on this news
Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19 - IMM-BCP-01 targets three non-overlapping regions on the Spike protein to provide broad coverag
Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment - IMM-BCP-01 targets three non-overlapping regions on the Spike protein to provide broad coverage across CDC current and former variants of concern elicits multi-mod
Read more →IMNMHarnessing the Human Memory B Cell Response To Develop Antibody - Based Therapeutics
25 Novel Insights from Discovery Engine 1. Adv Clin Chem. 2016;74:103 - 41.DOI: 10.1016/bs.acc.2015.12.005 2. Mol Cancer. 2019 Oct 23;18(1):146. doi : 10.1186/s12943 - 019 - 1074 - 3 3. Including some commercially - validated targets such as ERBB2 Provides Critical Insights Into
Read more →IMNM▲ +14.9%on this news
Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing - IMM-BCP-01 already shown to neutralize all other Center for Disease Control (CDC) variants of concer
Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing IMM-BCP-01 already shown to neutralize all other Center for Disease Control (CDC) variants of concern in pre-clinical testing - PA - September 7, 2021 - Immunome, Inc. (
Read more →IMNM▲ +9%on this news
Copyright 2021 Immunome, Inc. All rights reserved. Harnessing the Human Memory B Cell Response To Develop Antibody - Based Therapeutics
MD Mayo Clinic Professor, Infectious Diseases and Chair, COVID - 19 Research Taskforce Professor & Chair, Department of Molecular Medicine, Michael Diamond , MD, PhD Washington University School of Medicine The Herbert S. Gasser Professor of Medicine and Professor of Molecular Bi
Read more →IMNMImmunome Appoints Franklyn G. Prendergast, M.D., Ph.D. to Board of Directors - Dr. Prendergast is a renowned scientific researcher with over 45 years of association with the Mayo Foundation and over 20 years' experience
Immunome Appoints Franklyn G. Prendergast, M.D., - Dr. Prendergast is a renowned scientific researcher with over 45 years of association with the Mayo Foundation and over 20 years' experience as a non-executive director of Eli Lilly - Exton, Pa., June 17, 2021 - Immunome, Inc
Read more →IMNMImmunome Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern - Additional $4.3 million in funding brings total DOD funding to $17.6 million. - Ant
Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern - Additional $4.3 million in funding brings total DOD funding to - Antibody cocktail (IMM-BCP-01) is a combination of three antibodies that bind to complementary
Read more →IMNMImmunome Reports First Quarter 2021 Financial Results - IMM-BCP-01: Selected antibody cocktail demonstrating neutralization of CDC SARS-CoV-2 "variants of concern" in preclinical testing, progressing towards IND filing -
Immunome Reports First Quarter 2021 Financial - IMM-BCP-01: Selected antibody cocktail demonstrating neutralization of CDC SARS-CoV-2 "variants of concern" in preclinical testing, progressing towards IND filing - - IMM-ONC-01: Advanced proprietary antibody against IL-38, a no
Read more →IMNMImmunome Announces $27 Million Private Placement Exton, PA
Announces $27 Million Private Placement Exton, PA, April 26, 2021 - Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, today announced it has e
Read more →IMNMImmunome Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update - IMM-BCP-01: Isolated antibodies capable of neutralizing SARS-CoV-2 variants, including the South African variant (B.1.351)
Immunome Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update - IMM-BCP-01: Isolated antibodies capable of neutralizing SARS-CoV-2 variants, including the South African variant (B.1.351), in pseudovirus testing - - IMM-ONC-01: Advanced propri
Read more →IMNMCopyright 2021 Immunome, Inc. All rights reserved. Harnessing the Human Memory B Cell Response To Develop Antibody - Based Therapeutics Immunome, Inc. 665 Stockton Drive, Suite 300 Exton, PA 19341 610.321.3700 www.immuno
Gasser Professor of Medicine and Professor of Molecular Biology Pathology and Immunology Associate Director, for the Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs Jeffery Henderson , MD, PhD Washington University Associate Professor of Medici
Read more →IMNMImmunome Reports Third Quarter 2020 Financial Results and Significant Progress - Completed $44.9M IPO in October - - Identified COVID 19 Neutralizing antibodies - - Significant progress made on lead programs, including I
Immunome Reports Third Quarter 2020 Financial Results and Significant Progress - Completed $44.9M IPO in October - - Identified COVID 19 Neutralizing antibodies - - Significant progress made on lead programs, including IMM-BCP-01 for the treatment of COVID-19 in collaboration
Read more →IMNMDeveloping Antibody - Based Therapeutics by Unlocking the Human Memory B Cell Response Immunome, Inc. 665 Stockton Drive, Suite 300 Exton, PA 19341 610.321.3700 www.immunome.com
Developing Antibody - Based Therapeutics by Unlocking the Human Memory B Cell Response Immunome, Inc. 665 Stockton Drive, Suite 300 Exton, PA 19341 610.321.3700 www.immunome.com October 26, 2020 This presentation contains "forward - looking statements" within the meaning of the
Read more →Competitive Position
How IMNM ranks across every disease it competes inCompetitive Position is a premium feature
See how IMNM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial